202 related articles for article (PubMed ID: 33544215)
1. Normalization of electroretinogram and symptom resolution of melanoma-associated retinopathy with negative autoantibodies after treatment with programmed death-1 (PD-1) inhibitors for metastatic melanoma.
Khaddour K; Khanna S; Ansstas M; Jakhar I; Dahiya S; Council L; Ansstas G
Cancer Immunol Immunother; 2021 Sep; 70(9):2497-2502. PubMed ID: 33544215
[TBL] [Abstract][Full Text] [Related]
2. Outcomes Associated With Sustained-Release Intraocular Fluocinolone Implants in a Case of Melanoma-Associated Retinopathy Treated Without Systemic Immunosuppression.
Karatsai E; Robson AG; Taylor SRJ
JAMA Ophthalmol; 2019 May; 137(5):564-567. PubMed ID: 30896772
[TBL] [Abstract][Full Text] [Related]
3. Melanoma-associated retinopathy with anti-TRPM1 autoantibodies showing concomitant Off-bipolar cell dysfunction.
Hung WC; Cheng HC; Wang AG
Doc Ophthalmol; 2022 Dec; 145(3):263-270. PubMed ID: 36173494
[TBL] [Abstract][Full Text] [Related]
4. [Paraneoplastic retinopathy].
Liu Y; Lei B
Zhonghua Yan Ke Za Zhi; 2012 Jul; 48(7):653-6. PubMed ID: 22943872
[TBL] [Abstract][Full Text] [Related]
5. Melanoma-associated retinopathy during pembrolizumab treatment probably controlled by intravitreal injections of dexamethasone.
Poujade L; Samaran Q; Mura F; Guillot B; Meunier I; Du-Thanh A
Doc Ophthalmol; 2021 Apr; 142(2):257-263. PubMed ID: 32975694
[TBL] [Abstract][Full Text] [Related]
6. Diagnosis of occult melanoma using transient receptor potential melastatin 1 (TRPM1) autoantibody testing: a novel approach.
Dalal MD; Morgans CW; Duvoisin RM; Gamboa EA; Jeffrey BG; Garg SJ; Chan CC; Sen HN
Ophthalmology; 2013 Dec; 120(12):2560-2564. PubMed ID: 24053997
[TBL] [Abstract][Full Text] [Related]
7. Serum TRPM1 autoantibodies from melanoma associated retinopathy patients enter retinal on-bipolar cells and attenuate the electroretinogram in mice.
Xiong WH; Duvoisin RM; Adamus G; Jeffrey BG; Gellman C; Morgans CW
PLoS One; 2013; 8(8):e69506. PubMed ID: 23936334
[TBL] [Abstract][Full Text] [Related]
8. Lesson of the month 1: Seeing snowflakes.
Patel A; Aslam A; Orr G; Perkins W
Clin Med (Lond); 2015 Aug; 15(4):394-5. PubMed ID: 26407395
[TBL] [Abstract][Full Text] [Related]
9. Melanoma-associated retinopathy treated with ipilimumab therapy.
Audemard A; de Raucourt S; Miocque S; Comoz F; Giraud JM; Dreno B; Bienvenu B; Rogerie MJ; Dompmartin A
Dermatology; 2013; 227(2):146-9. PubMed ID: 24051549
[TBL] [Abstract][Full Text] [Related]
10. A case of melanoma-associated retinopathy with autoantibodies against TRPM1.
Kim MS; Hong HK; Ko YJ; Park KH; Ueno S; Okado S; Woo SJ; Joo K
Doc Ophthalmol; 2020 Dec; 141(3):313-318. PubMed ID: 32472235
[TBL] [Abstract][Full Text] [Related]
11. Ipilimumab alone or ipilimumab plus anti-PD-1 therapy in patients with metastatic melanoma resistant to anti-PD-(L)1 monotherapy: a multicentre, retrospective, cohort study.
Pires da Silva I; Ahmed T; Reijers ILM; Weppler AM; Betof Warner A; Patrinely JR; Serra-Bellver P; Allayous C; Mangana J; Nguyen K; Zimmer L; Trojaniello C; Stout D; Lyle M; Klein O; Gerard CL; Michielin O; Haydon A; Ascierto PA; Carlino MS; Lebbe C; Lorigan P; Johnson DB; Sandhu S; Lo SN; Blank CU; Menzies AM; Long GV
Lancet Oncol; 2021 Jun; 22(6):836-847. PubMed ID: 33989557
[TBL] [Abstract][Full Text] [Related]
12. Autoantibody against transient receptor potential M1 cation channels of retinal ON bipolar cells in paraneoplastic vitelliform retinopathy.
Wang Y; Abu-Asab MS; Li W; Aronow ME; Singh AD; Chan CC
BMC Ophthalmol; 2012 Nov; 12():56. PubMed ID: 23148706
[TBL] [Abstract][Full Text] [Related]
13. Antiepidermis autoantibodies induced by anti-PD-1 therapy in metastatic melanoma.
Brunet-Possenti F; Mignot S; Deschamps L; Descamps V
Melanoma Res; 2016 Oct; 26(5):540-3. PubMed ID: 27482939
[TBL] [Abstract][Full Text] [Related]
14. Encephalitis Associated With Immune Checkpoint Inhibitor Treatment in Patients With Melanoma.
Martínez-Vila C; Laguna JC; Segui E; Ruiz G; Aya Moreno F; Fernandez-Morales LM; Giner Joaquim J; Padrosa J; Fernandez L; Gaba L; Victoria I; Arance Fernandez AM
J Immunother; 2021 Jun; 44(5):204-207. PubMed ID: 33950029
[TBL] [Abstract][Full Text] [Related]
15. Melanoma-associated retinopathy.
Elsheikh S; Gurney SP; Burdon MA
Clin Exp Dermatol; 2020 Mar; 45(2):147-152. PubMed ID: 31742740
[TBL] [Abstract][Full Text] [Related]
16. Presumed melanoma-associated retinopathy (MAR): a presenting sign of primary small intestinal melanoma?
Rappoport D; Leiba H
Int Ophthalmol; 2012 Aug; 32(4):387-91. PubMed ID: 22527450
[TBL] [Abstract][Full Text] [Related]
17. Association of Anti-Programmed Cell Death 1 Antibody Treatment With Risk of Recurrence of Toxic Effects After Immune-Related Adverse Events of Ipilimumab in Patients With Metastatic Melanoma.
Brunot A; Grob JJ; Jeudy G; Grange F; Guillot B; Kramkimel N; Mortier L; Le Corre Y; Aubin FF; Mansard S; Lebbé C; Blom A; Montaudie H; Giacchero D; Prey S; Legoupil D; Guyot A; Amini-Adle M; Granel-Brocard F; Meyer N; Dinulescu M; Edeline J; Campillo-Gimenez B; Lesimple T
JAMA Dermatol; 2020 Sep; 156(9):982-986. PubMed ID: 32667663
[TBL] [Abstract][Full Text] [Related]
18. In-depth plasma proteomics reveals increase in circulating PD-1 during anti-PD-1 immunotherapy in patients with metastatic cutaneous melanoma.
Babačić H; Lehtiö J; Pico de Coaña Y; Pernemalm M; Eriksson H
J Immunother Cancer; 2020 May; 8(1):. PubMed ID: 32457125
[TBL] [Abstract][Full Text] [Related]
19. Treatment Options for Advanced Melanoma After Anti-PD-1 Therapy.
Babacan NA; Eroglu Z
Curr Oncol Rep; 2020 Mar; 22(4):38. PubMed ID: 32198651
[TBL] [Abstract][Full Text] [Related]
20. The Next Immune-Checkpoint Inhibitors: PD-1/PD-L1 Blockade in Melanoma.
Mahoney KM; Freeman GJ; McDermott DF
Clin Ther; 2015 Apr; 37(4):764-82. PubMed ID: 25823918
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
